The contract research organization PPD Inc. is paying Eli Lilly and Co. $65 million in cash - about 37 percent of its available funds - for the patents related to dapoxetine, a selective serotonin reuptake inhibitor in late Phase III trials by Johnson & Johnson for premature ejaculation. (BioWorld Today)

Lexicon Genetics Inc. entered an agreement focused on neuroscience with Bristol-Myers Squibb Co. that provides an up-front payment of $36 million, with at least $30 million more in research funding during the next three years - and potentially another $50 million, if the deal is extended. (BioWorld Today)

BioNumerik Pharmaceuticals Inc. is topping off 2003 with more than $35 million in cash, thanks to a $29 million private placement with existing investors. (BioWorld Today)